Methods of preventing viral replication
AssigneeThe General Hospital Corporation
InventorsHubert E. Blum, Tsanyang Liang, Eithan Galun, Jack R. Wands
Life of this patent
Estimating the term…
Abstract
The invention relates to methods and compositions for inhibition of viral replication. In particular, termination of replication of hepatitis B virus is achieved by introducing into a target cell an antisense oligonucleotide having a sequence substantially complementary to an mRNA which is in turn complementary to a portion of the minus strand of a hepatitis viral genome, which portion encoding solely part or all of the terminal protein region of the viral polymerase.
Claims26
A method for inhibiting replication of hepatitis B virus in a cultured cell, comprising introducing into said cell an antiviral antisense oligonucleotide the sequence of which consists of 12 to 40 contiguous nucleotides of (a) ATC-40:
- ATA TGG TGA CCC GCA AAA TGA TGC GCT ACG TGT GGG TTC C (SEQ ID NO:
- 11), or (b) the RNA equivalent of ATC-40, whereby hepatitis B virus replication is inhibited.
A composition of matter consisting essentially of at least one antisense oligonucleotide having antiviral activity against HBV, the sequence of which oligonucleotide consists of 12 to 40 contiguous nucleotides of (a) ATC-40:
- ATA TGG TGA CCC GCA AAA TGA TGC GCT ACG TGT GGG TTC C (SEQ ID NO:
- 11), or (b) the RNA equivalent of ATC-40.
A nucleic acid which (a) can be replicated in a hepatocyte, and (b) is transcribed in a hepatocyte to produce an antiviral antisense oligoribonucleotide the sequence of consists of 12 to 40 contiguous nucleotides of the RNA equivalent of ATC-40:
- ATA TGG TGA CCC GCA AAA TGA TGC GCT ACG TGT GGG TTC C (SEQ ID NO:
- 11).
Dependencies are inferred from the claim text.